JP2015512947A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015512947A5 JP2015512947A5 JP2015505959A JP2015505959A JP2015512947A5 JP 2015512947 A5 JP2015512947 A5 JP 2015512947A5 JP 2015505959 A JP2015505959 A JP 2015505959A JP 2015505959 A JP2015505959 A JP 2015505959A JP 2015512947 A5 JP2015512947 A5 JP 2015512947A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- patient
- pharmaceutical composition
- disease
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 65
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 25
- 229910052805 deuterium Inorganic materials 0.000 claims description 25
- 229910052739 hydrogen Inorganic materials 0.000 claims description 24
- 239000001257 hydrogen Substances 0.000 claims description 24
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 8
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 6
- 206010022489 Insulin Resistance Diseases 0.000 claims description 4
- 206010022562 Intermittent claudication Diseases 0.000 claims description 4
- 208000020832 chronic kidney disease Diseases 0.000 claims description 4
- 208000021156 intermittent vascular claudication Diseases 0.000 claims description 4
- 230000007850 degeneration Effects 0.000 claims description 3
- 230000000155 isotopic effect Effects 0.000 claims description 3
- 208000019423 liver disease Diseases 0.000 claims description 3
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 2
- 200000000007 Arterial disease Diseases 0.000 claims description 2
- 206010056340 Diabetic ulcer Diseases 0.000 claims description 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 208000004930 Fatty Liver Diseases 0.000 claims description 2
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 2
- 201000005569 Gout Diseases 0.000 claims description 2
- 208000015023 Graves' disease Diseases 0.000 claims description 2
- 206010019663 Hepatic failure Diseases 0.000 claims description 2
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 2
- 206010019728 Hepatitis alcoholic Diseases 0.000 claims description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 206010055171 Hypertensive nephropathy Diseases 0.000 claims description 2
- 201000001431 Hyperuricemia Diseases 0.000 claims description 2
- 208000010038 Ischemic Optic Neuropathy Diseases 0.000 claims description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 2
- 208000005777 Lupus Nephritis Diseases 0.000 claims description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 2
- 206010028851 Necrosis Diseases 0.000 claims description 2
- 206010029164 Nephrotic syndrome Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 206010030924 Optic ischaemic neuropathy Diseases 0.000 claims description 2
- 206010033645 Pancreatitis Diseases 0.000 claims description 2
- 206010033647 Pancreatitis acute Diseases 0.000 claims description 2
- 208000003251 Pruritus Diseases 0.000 claims description 2
- 208000033626 Renal failure acute Diseases 0.000 claims description 2
- 208000017442 Retinal disease Diseases 0.000 claims description 2
- 206010038923 Retinopathy Diseases 0.000 claims description 2
- 208000018020 Sickle cell-beta-thalassemia disease syndrome Diseases 0.000 claims description 2
- 206010043391 Thalassaemia beta Diseases 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 208000026723 Urinary tract disease Diseases 0.000 claims description 2
- 208000012931 Urologic disease Diseases 0.000 claims description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 2
- 201000011040 acute kidney failure Diseases 0.000 claims description 2
- 201000003229 acute pancreatitis Diseases 0.000 claims description 2
- 208000012998 acute renal failure Diseases 0.000 claims description 2
- 208000002353 alcoholic hepatitis Diseases 0.000 claims description 2
- 208000007502 anemia Diseases 0.000 claims description 2
- 201000007058 anterior ischemic optic neuropathy Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 230000007882 cirrhosis Effects 0.000 claims description 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 2
- 230000037213 diet Effects 0.000 claims description 2
- 235000005911 diet Nutrition 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 208000010706 fatty liver disease Diseases 0.000 claims description 2
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 claims description 2
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 claims description 2
- 231100000268 induced nephrotoxicity Toxicity 0.000 claims description 2
- 208000007903 liver failure Diseases 0.000 claims description 2
- 231100000835 liver failure Toxicity 0.000 claims description 2
- 208000002780 macular degeneration Diseases 0.000 claims description 2
- 230000017074 necrotic cell death Effects 0.000 claims description 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 208000030761 polycystic kidney disease Diseases 0.000 claims description 2
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- 208000004644 retinal vein occlusion Diseases 0.000 claims description 2
- 208000007056 sickle cell anemia Diseases 0.000 claims description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 2
- 208000014001 urinary system disease Diseases 0.000 claims description 2
- 208000017667 Chronic Disease Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-VVKOMZTBSA-N Dideuterium Chemical compound [2H][2H] UFHFLCQGNIYNRP-VVKOMZTBSA-N 0.000 claims 1
- 208000003807 Graves Disease Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 230000003412 degenerative effect Effects 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 208000010227 enterocolitis Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 210000001927 retinal artery Anatomy 0.000 claims 1
- 201000005665 thrombophilia Diseases 0.000 claims 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 13
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 0 **(C(*)(*C1c2c(N3*)nc(*)[n]2*)C(*)(*)C(*)(*)C(*)(*)*)N1C3=O Chemical compound **(C(*)(*C1c2c(N3*)nc(*)[n]2*)C(*)(*)C(*)(*)C(*)(*)*)N1C3=O 0.000 description 6
- MRWQRJMESRRJJB-UHFFFAOYSA-N pentifylline Chemical compound O=C1N(CCCCCC)C(=O)N(C)C2=C1N(C)C=N2 MRWQRJMESRRJJB-UHFFFAOYSA-N 0.000 description 4
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 150000002431 hydrogen Chemical group 0.000 description 2
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 2
- 229960002371 pentifylline Drugs 0.000 description 2
- 208000023328 Basedow disease Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 201000007527 Retinal artery occlusion Diseases 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261623858P | 2012-04-13 | 2012-04-13 | |
| US61/623,858 | 2012-04-13 | ||
| PCT/US2013/036454 WO2013155465A1 (en) | 2012-04-13 | 2013-04-12 | Substituted xanthine derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015512947A JP2015512947A (ja) | 2015-04-30 |
| JP2015512947A5 true JP2015512947A5 (enExample) | 2016-06-09 |
Family
ID=48184515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015505959A Pending JP2015512947A (ja) | 2012-04-13 | 2013-04-12 | 置換キサンチン誘導体 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9328113B2 (enExample) |
| EP (1) | EP2836492B1 (enExample) |
| JP (1) | JP2015512947A (enExample) |
| KR (1) | KR20150002779A (enExample) |
| CN (1) | CN104364255A (enExample) |
| AU (1) | AU2013245662A1 (enExample) |
| CA (1) | CA2869874A1 (enExample) |
| EA (1) | EA201491878A8 (enExample) |
| IN (1) | IN2014DN08443A (enExample) |
| MX (1) | MX2014012384A (enExample) |
| WO (1) | WO2013155465A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8263601B2 (en) | 2009-02-27 | 2012-09-11 | Concert Pharmaceuticals, Inc. | Deuterium substituted xanthine derivatives |
| EP3377179B1 (en) | 2015-11-19 | 2021-04-07 | Concert Pharmaceuticals Inc. | Deuterated epi-743 |
| US11731947B2 (en) | 2019-04-10 | 2023-08-22 | University Of Notre Dame Du Lac | Deuterated antimicrobial compounds |
| TW202227085A (zh) * | 2020-09-14 | 2022-07-16 | 美商萊罕製藥股份有限公司 | 氘代副黃嘌呤(paraxanthine)及其用途 |
| US12194046B2 (en) | 2021-03-09 | 2025-01-14 | Lennham Pharmaceuticals, Inc. | D9-caffeine compositions and uses thereof |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE860217C (de) | 1950-10-28 | 1952-12-18 | Albert Ag Chem Werke | Verfahren zur Herstellung von 1-Hexyl-3, 7-dimethylxanthin |
| JPS5576876A (en) | 1978-12-05 | 1980-06-10 | Grelan Pharmaceut Co Ltd | Preparation of 1-(oxoalkyl)-3,7-dimethylxanthine derivatne |
| JPS55122779A (en) | 1979-03-13 | 1980-09-20 | Maruko Seiyaku Kk | Preparation of theobromine derivative |
| CS201558B1 (en) | 1979-05-14 | 1980-11-28 | Pavol Kovar | Method of preparing 1-/5-oxohexyl/-3,7-dimethylxanthine |
| JPS567785A (en) | 1979-07-02 | 1981-01-27 | Maruko Seiyaku Kk | Preparation of theobromine derivative |
| JPS5610187A (en) | 1979-07-05 | 1981-02-02 | Grelan Pharmaceut Co Ltd | Separation and purification of 1-(5-oxohexyl)- 3,7-dimethylxanthine |
| JPS5610188A (en) | 1979-07-06 | 1981-02-02 | Dainippon Ink & Chem Inc | Xanthine derivative and its preparation |
| JPS5632477A (en) | 1979-08-27 | 1981-04-01 | Nippon Iyakuhin Kaihatsu Kenkyusho:Kk | Preparation of 1- 5-oxohexyl -3,7-dimethylxanthine |
| JPS5677279A (en) | 1979-11-28 | 1981-06-25 | Ota Seiyaku Kk | Preparation of xanthine derivative |
| JPS5711981A (en) | 1980-06-26 | 1982-01-21 | Sagami Chem Res Center | Theobromine derivative and its preparation |
| JPS5724382A (en) | 1980-07-17 | 1982-02-08 | Nissan Chem Ind Ltd | Trithiane derivative and its preparation |
| JPS5724385A (en) | 1980-07-17 | 1982-02-08 | Nissan Chem Ind Ltd | Theobromine derivative and its preparation |
| JPS5724386A (en) | 1980-07-17 | 1982-02-08 | Nissan Chem Ind Ltd | Preparation of xanthine derivative |
| JPS5756481A (en) | 1980-09-22 | 1982-04-05 | Kawashima Yakuhin Kaihatsu Kk | Production of 1-(5-oxohexyl)-3,7-dimethylxanthine |
| JPS5762278A (en) | 1980-10-01 | 1982-04-15 | Sagami Chem Res Center | Theobromine derivative and its preparation |
| JPS5780385A (en) | 1980-11-05 | 1982-05-19 | Mitsubishi Petrochem Co Ltd | Preparation of 1-((omega-1)-oxoalkyl)-3,7-dialkylxanthine |
| JPS5785387A (en) | 1980-11-14 | 1982-05-28 | Teikoku Chem Ind Corp Ltd | Preparation of 1-(-5'-oxohexyl)-3,7-dimethylxanthine |
| JPS5798284A (en) | 1980-12-10 | 1982-06-18 | Kawashima Yakuhin Kaihatsu Kk | Preparation of 1-(5-oxohexyl)-3,7-dimethylxanthine |
| JPS57200391A (en) | 1981-06-02 | 1982-12-08 | Daito Koeki Kk | 1-(5-oxo-2-hexenyl)3,7-dimethylxanthine |
| JPS5838284A (ja) | 1981-09-01 | 1983-03-05 | Teikoku Chem Ind Corp Ltd | １−（５′−オキソヘキシル）−３，７−ジメチルキサンチンの製造方法 |
| JPS58134092A (ja) | 1982-02-05 | 1983-08-10 | Sagami Chem Res Center | テオブロミン誘導体 |
| JPS58150594A (ja) | 1982-03-03 | 1983-09-07 | Daito Koeki Kk | キサンチン誘導体の製造方法 |
| CS237719B1 (cs) | 1983-05-12 | 1985-10-16 | Jan Jendrichovsky | SpAsob přípravy dimetyl-(5-oxohexyl)-xantlnov |
| DE3508097A1 (de) | 1984-07-21 | 1986-02-06 | Hoechst Ag, 6230 Frankfurt | Kombinationspraeparat aus xanthinderivaten und o-acetylsalicylsaeure bzw. deren pharmakologisch vertraeglichen salzen und dessen verwendung |
| DE3525801A1 (de) | 1985-07-19 | 1987-01-22 | Hoechst Ag | Tertiaere hydroxyalkylxanthine, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung |
| DD274334A3 (de) | 1985-12-17 | 1989-12-20 | Dresden Arzneimittel | Verfahren zur herstellung von reinem 3,7-dimethyl-1-(5-oxohexyl)-xanthin |
| IL106859A (en) | 1986-12-31 | 1996-10-16 | Hoechst Roussel Pharma | Pentoxifilin metabolites and pharmaceutical preparations containing them for the treatment of VIH and similar diseases |
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5112827A (en) | 1990-05-18 | 1992-05-12 | Board Of Regents, The University Of Texas System | Drug to reverse fatty liver and atheromatous lesions |
| WO1992007566A2 (en) | 1990-11-01 | 1992-05-14 | Board Of Regents, The University Of Texas System | Antifungal activity of and prevention of drug induced nephrotoxicity by methylxanthine analogues |
| ATE138266T1 (de) | 1990-11-07 | 1996-06-15 | Hoechst Roussel Pharma | Verwendung von xanthinen zur herstellung von arzneimitteln zur hemmung der vermehrung menschlicher retroviren |
| EP0490181A1 (en) | 1990-11-30 | 1992-06-17 | Hoechst-Roussel Pharmaceuticals Incorporated | Use of xanthines for preparation of a medicament having immunosuppressing activity |
| US6420374B1 (en) | 1990-11-30 | 2002-07-16 | Fred Hutchinson Cancer Research Center | Use of xanthines as immunosuppressants and to inhibit allograft reactions |
| EP0493682A3 (en) | 1990-11-30 | 1992-11-19 | Hoechst-Roussel Pharmaceuticals Incorporated | Use of xanthines for the preparation of a medicament effective for inhibiting the effects of allograft reaction in humans |
| US5648357A (en) | 1992-03-04 | 1997-07-15 | Cell Therapeutics, Inc. | Enatiomerically pure hydroxylated xanthine compounds |
| US5763446A (en) | 1992-03-26 | 1998-06-09 | University Of Southern California | Use of pentoxifylline and other tumor necrosis factor blockers for the treatment of aids-associated optic neuropathy and other central nervous system diseases |
| US5780476A (en) | 1992-11-16 | 1998-07-14 | Cell Therapeutics, Inc. | Hydroxyl-containing xanthine compounds |
| US5670506A (en) | 1993-04-05 | 1997-09-23 | Cell Therapeutics, Inc. | Halogen, isothiocyanate or azide substituted xanthines |
| US6020337A (en) | 1993-04-05 | 2000-02-01 | Cell Therapeutics, Inc. | Electronegative-substituted long chain xanthine compounds |
| US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
| HUT68560A (en) | 1993-08-02 | 1995-04-27 | Chinoin Gyogyszer Es Vegyeszet | The use of xantine derivatives for promotion of healing of operative lesions |
| US6221335B1 (en) | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| CA2186371A1 (en) | 1994-03-25 | 1995-10-05 | Robert T. Foster | Enhancement of the efficacy of dihydropyridines by deuteration |
| JPH10507156A (ja) | 1994-05-16 | 1998-07-14 | セル・セラピューティックス・インコーポレーテッド | キラル第二級アルコールの不斉合成 |
| WO1996005836A2 (en) | 1994-08-25 | 1996-02-29 | Medical University Of South Carolina | Methods of treating cold symptoms using pentoxifylline |
| DE4430127A1 (de) | 1994-08-25 | 1996-03-14 | Hoechst Ag | Kombinationspräparat, enthaltend Cyclosporin A oder FK506 und ein Xanthinderivat |
| DE4430128A1 (de) | 1994-08-25 | 1996-02-29 | Hoechst Ag | Kombinationspräparat mit immunsuppressiven, kardiovaskulären und cerebralen Wirkungen |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| DE19544768C1 (de) | 1995-11-30 | 1997-07-10 | Rentschler Arzneimittel | Verwendung einer Kombination aus Pentoxifyllin mit Typ-I-Interferonen zur Behandlung der Multiplen Sklerose |
| US5985592A (en) | 1997-06-05 | 1999-11-16 | Dalhousie University | Uses for pentoxifylline or functional derivatives/metabolites thereof |
| US6294350B1 (en) | 1997-06-05 | 2001-09-25 | Dalhousie University | Methods for treating fibroproliferative diseases |
| US6440710B1 (en) | 1998-12-10 | 2002-08-27 | The Scripps Research Institute | Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds |
| US6316458B1 (en) | 1999-04-30 | 2001-11-13 | Cell Therapeutics, Inc. | Method of enhancing insulin action |
| GB9925962D0 (en) | 1999-11-02 | 1999-12-29 | Novartis Ag | Organic compounds |
| PT1104760E (pt) * | 1999-12-03 | 2003-06-30 | Pfizer Prod Inc | Compostos de sulfamoil-heteroarilpirazole como agentes analgesicos e anti-inflamatorios |
| BR0209325A (pt) | 2001-05-03 | 2004-07-20 | Hoffmann La Roche | Forma de dosagem farmacêutica de mesilato de nelfinavir amorfo |
| EP1392262A1 (en) | 2001-05-24 | 2004-03-03 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
| WO2003013568A1 (en) | 2001-08-02 | 2003-02-20 | Ortho-Mcneil Pharmaceutical, Inc. | Cytokine modulation therapy |
| US20050107420A1 (en) | 2002-05-23 | 2005-05-19 | Boehringe Ingelheim Pharma Gmbh & Co. Kg | Combination of a PDE4 inhibitor and tiotropium or derivative thereof for treating obstructive airways and other inflammatory diseases |
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| TW200413273A (en) | 2002-11-15 | 2004-08-01 | Wako Pure Chem Ind Ltd | Heavy hydrogenation method of heterocyclic rings |
| WO2005023193A2 (en) | 2003-09-04 | 2005-03-17 | Interleukin Genetics, Inc. | Methods of treating endometriosis |
| WO2006035418A2 (en) | 2004-09-27 | 2006-04-06 | Sigmoid Biotechnologies Limited | Microcapsules comprising a methylxanthine and a corticosteroid |
| CA2581169A1 (en) | 2004-09-29 | 2006-04-13 | Cordis Corporation | Pharmaceutical dosage forms of stable amorphous rapamycin like compounds |
| CN101309917B (zh) | 2005-10-06 | 2013-09-11 | 奥斯拜客斯制药有限公司 | 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂 |
| US7750168B2 (en) | 2006-02-10 | 2010-07-06 | Sigma-Aldrich Co. | Stabilized deuteroborane-tetrahydrofuran complex |
| JO2630B1 (en) | 2006-04-13 | 2012-06-17 | نوفارتيس ايه جي | Organic compounds |
| CA2661404A1 (en) | 2006-09-05 | 2008-03-13 | Schering Corporation | Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis |
| MX2010009300A (es) | 2008-02-29 | 2010-11-05 | Concert Pharmaceuticals Inc | Derivados de xantina substituidos. |
| US20110053961A1 (en) | 2009-02-27 | 2011-03-03 | Concert Pharmaceuticals, Inc. | Substituted xanthine derivatives |
| US8263601B2 (en) | 2009-02-27 | 2012-09-11 | Concert Pharmaceuticals, Inc. | Deuterium substituted xanthine derivatives |
| JP2013503883A (ja) | 2009-09-02 | 2013-02-04 | コンサート ファーマシューティカルズ インコーポレイテッド | 置換キサンチン誘導体 |
-
2013
- 2013-04-12 IN IN8443DEN2014 patent/IN2014DN08443A/en unknown
- 2013-04-12 CA CA 2869874 patent/CA2869874A1/en not_active Abandoned
- 2013-04-12 KR KR1020147031315A patent/KR20150002779A/ko not_active Withdrawn
- 2013-04-12 EA EA201491878A patent/EA201491878A8/ru unknown
- 2013-04-12 US US14/391,443 patent/US9328113B2/en active Active
- 2013-04-12 CN CN201380031266.6A patent/CN104364255A/zh active Pending
- 2013-04-12 WO PCT/US2013/036454 patent/WO2013155465A1/en not_active Ceased
- 2013-04-12 MX MX2014012384A patent/MX2014012384A/es unknown
- 2013-04-12 EP EP13718735.7A patent/EP2836492B1/en active Active
- 2013-04-12 JP JP2015505959A patent/JP2015512947A/ja active Pending
- 2013-04-12 AU AU2013245662A patent/AU2013245662A1/en not_active Abandoned